Alcoholic hepatitis

This study tested a drug called INT-787 in 67 people with severe alcohol-associated hepatitis, a serious liver condition. The trial was a phase 2a proof-of-concept study, but it was terminated early. Researchers were looking at safety, how well the drug works, and how the body pr…

This small, early-phase study tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive intravenous digoxin or no digoxin for up to 28 days. The trial was terminated …

This study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …

This study tested a program to help HIV-negative transgender women and men who have sex with men who also have a substance use disorder stick with PrEP, a daily pill or shot that prevents HIV. Participants received counseling and text support, with extra help for those who strugg…

This study tested whether adding vaccine discussions to routine behavioral health visits could reduce hesitancy and increase COVID-19 and flu shots among Latinx adults with mental illness. Clinicians used motivational interviewing and could offer a warm handoff to a nurse for vac…

This study tested a small device worn on the ear that uses mild electrical pulses to help control pain after a liver transplant. The goal was to see if it could reduce the need for strong painkillers like opioids. The study was stopped early and included 27 adults waiting for a l…

This study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …

This early-stage study looked at how the drug amcenestrant is processed in the body of women aged 40-75 with mild or moderate liver problems, compared to women with healthy livers. The goal was to understand dosing and safety. However, the trial was terminated before completion, …